# Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

> **NCT07185945** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guru Sonpavde** · enrollment: 44 (estimated)

## Conditions studied

- Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07185945
- **Lead sponsor:** Guru Sonpavde
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-06
- **Final completion:** 2029-06
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185945, "Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07185945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*